Advil Allergy Sinus is owned by Glaxosmithkline.
Advil Allergy Sinus contains Chlorpheniramine Maleate; Ibuprofen; Pseudoephedrine Hydrochloride.
Advil Allergy Sinus has a total of 1 drug patent out of which 0 drug patents have expired.
Advil Allergy Sinus was authorised for market use on 19 December, 2002.
Advil Allergy Sinus is available in tablet;oral dosage forms.
The generics of Advil Allergy Sinus are possible to be released after 28 February, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7863287||GLAXOSMITHKLINE||Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines|| |
(4 years from now)
Market Authorisation Date: 19 December, 2002
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic